CSBTF Stock - Kuros Biosciences AG
Unlock GoAI Insights for CSBTF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $75.56M | $33.56M | $17.99M | $13.81M | $4.04M |
| Gross Profit | $62.03M | $28.47M | $10.77M | $10.07M | $1.67M |
| Gross Margin | 82.1% | 84.8% | 59.9% | 72.9% | 41.4% |
| Operating Income | $-4,995,000 | $-13,192,000 | $-13,446,000 | $-8,767,000 | $-11,679,000 |
| Net Income | $-3,716,000 | $-13,727,000 | $-14,595,000 | $-7,541,000 | $-11,520,000 |
| Net Margin | -4.9% | -40.9% | -81.1% | -54.6% | -285.2% |
| EPS | $-0.10 | $-0.38 | $-0.43 | $-0.23 | $-0.47 |
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.
Visit WebsiteEarnings History & Surprises
CSBTFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 9, 2026 | — | — | — | — |
Q3 2025 | Aug 14, 2025 | — | $-0.06 | — | — |
Q1 2025 | Mar 11, 2025 | — | $-0.10 | — | — |
Q4 2024 | Oct 10, 2024 | — | $-0.01 | — | — |
Q1 2024 | Mar 13, 2024 | — | $-0.28 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.15 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.34 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.12 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.25 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Q4 2020 | Dec 31, 2020 | $-0.34 | $-0.24 | +28.8% | ✓ BEAT |
Q2 2020 | Jun 30, 2020 | — | $-0.25 | — | — |
Q4 2019 | Dec 31, 2019 | $-0.34 | $-0.34 | +0.2% | ✓ BEAT |
Q3 2019 | Aug 20, 2019 | — | $-0.30 | — | — |
Q2 2019 | Apr 23, 2019 | — | $-0.72 | — | — |
Q3 2018 | Sep 5, 2018 | — | $-0.63 | — | — |
Q2 2018 | May 4, 2018 | — | $-1.22 | — | — |
Q3 2017 | Sep 26, 2017 | — | $-1.16 | — | — |
Q2 2017 | Apr 26, 2017 | — | $-1.25 | — | — |
Q4 2016 | Oct 4, 2016 | — | $-2.75 | — | — |
Latest News
Frequently Asked Questions about CSBTF
What is CSBTF's current stock price?
What is the analyst price target for CSBTF?
What sector is Kuros Biosciences AG in?
What is CSBTF's market cap?
Does CSBTF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CSBTF for comparison